Approach for defining human adenovirus infection and disease for central review adjudication in clinical studies
Year: 2024
Type: article
Abstract: BACKGROUND: Pediatric allogeneic hematopoietic cell transplant (allo-HCT) recipients are at risk for morbidity and mortality from human adenovirus (HAdV). HAdV can be detected in an asymptomatic state, referred to as infection or with signs or symptoms of illness, referred to as disease. Standardized case definitions are needed to distinguish infection from disease and allow for consistent reporting in both observational cohort studies and therapeutic clinical trials. METHODS: A working group of experts in virology, transplant infectious disease, and HCT was assembled to develop HAdV infection and disease definitions with the degree of certainty (i.e., possible, probable, and proven). Definitions were further refined through an iterative process and independently applied by two central review committees (CRCs) to 20 pediatric allo-HCT recipients with at least one HAdV-positive PCR. RESULTS: Initial HAdV infection and disease definitions were developed and updated through an iterative process after reviewing clinical and virological details for 81 subjects with at least one positive HAdV PCR detected in a clinical specimen. Independent application of final definitions to 20 HAdV positive allo-HCT recipients by two CRCs yielded similar number of HAdV infection or disease events but with variation of degree of certainty for some events. CONCLUSIONS: Application of definitions by a CRC for a study of HAdV infection and disease is feasible and can provide consistency in the assignment of outcomes. Definitions need further refinement to improve reproducibility and to provide guidance on determining clinical improvement or worsening after initial diagnosis of HAdV infection or disease.
Source: Pediatric Transplantation
DOI: 10.1111/petr.14750
Authors: Brian T. Fisher, Jesse Blumenstock, Craig L. K. Boge, Sydney Shuster, Alix E. Seif, Michael Green, Marian G. Michaels, Jessie L. Alexander, Monica I. Ardura, Tamara P. Miller, Diego R. Hijano, William J. Muller, Jennifer E. Schuster, Abby M. Green, Daniel E. Dulek, Adriana E. Kajon, Lara Danziger‐Isakov
Institutions: Children's Hospital of Philadelphia, University of Pennsylvania, UPMC Health System, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Nationwide Children's Hospital, The Ohio State University, Emory University, Children's Healthcare of Atlanta, St. Jude Children's Research Hospital, Northwestern University, Lurie Children's Hospital, Children's Mercy Hospital, Washington University in St. Louis, Monroe Carell Jr. Children's Hospital, Vanderbilt University Medical Center, Cincinnati Children's Hospital Medical Center, University of Cincinnati
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,730
Funders: U.S. Department of Health and Human Services, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, F. Hoffmann-La Roche, Immune Tolerance Network, Melinta Therapeutics, Nabriva Therapeutics, Moderna, Astellas Pharma, National Institutes of Health, U.S. Food and Drug Administration, National Institute of Allergy and Infectious Diseases, Janssen Biotech
Awards: G293477808, G6248468932
OpenAlex ID: W4394853565
